1. Ocular inflammatory events following COVID-19 vaccination: a multinational case series
- Author
-
Testi, I., Brandao-de-Resende, C., Agrawal, R., Pavesio, C., Steeples, L., Balasubramaniam, B., Mccluskey, P., Pichi, F., Agarwal, A., Herbort, C., Cimino, L., Iriqat, S., Thorne, J. E., Echegaray, J., Babu, K., Bialasiewicz, A. A., Goldstein, D. A., Ghadiri, N., Calduch, A. F., Andrade, G. C., Mahendradas, P., Gonzalez-Lopez, J. J., Carreno, E., Hamam, R. N., Stubiger, N., Bodaghi, B., Chao, Y. -J., Takeuchi, M., Tay-Kearney, M. -L., Portero, A., Keino, H., Esteban-Ortega, M., Przezdziecka-Dolyk, J., Radosavljevic, A., Paredes, I., Ling, H. S., Kiong, W., Tien, M., X. L., Ng, Chee, S. P., Siak, J., Hernanz-Rodriguez, I., Menezo, V., Tappeiner, C., Cruz, F. M., Addison, P., Kuijpers, R., Vasconcelos-Santos, D. V., Lee Kong Chian School of Medicine (LKCMedicine), Tan Tock Seng Hospital, Singapore Eye Research Institute, Duke NUS Medical School, Surgical clinical sciences, and Ophtalmology - Eye surgery
- Subjects
Immunomodulatory ,SARS-CoV-2 ,Vaccination ,Ocular inflammation ,COVID-19 ,RE1-994 ,vaccination ,infectious diseases ,Coronavirus disease ,Uveitis ,Ophthalmology ,Medicine [Science] ,Ocular Inflammation ,Original Research - Abstract
Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
- Published
- 2022